Abstract
Leflunomide (LEF) is a immunomodulator indicated in various diseases including rheumatoid arthritis. Recently, a link between this drug and pulmonary arterial hypertension (PAH) has been suggested (Lacoste Palasset et al., 2021, Ann Am Thorac Soc). Our aim was to examine the effect of LEF on pulmonary artery (PA) tone, whose abnormality is associated with PAH. Distal intralobar PAs and mesenteric arteries (MA) were isolated from male Wistar rats. PA were also collected from subjects with lung cancer, distal from tumor areas. PAs segments were mounted on a myograph for measurement of isometric tension and stimulated with various contractile agents and inhibitors. Experiments were conducted in the presence of LEF, its metabolite teriflunomide (TER) or vehicle (DMSO) (<0.7%). LEF (100 μM) dramatically inhibited the contractile response to high K + , phenylephrine (PE) and U46619 in rat PAs. LEF decreased E max of PE by 77% and induced a 3-fold increase in EC 50 compared to vehicle. Similar effects were observed in MA. Effect of LEF was unaffected by endothelium removal and was relieved after LEF wash out. Concentrations >10 μM of LEF produced a dose-dependent relaxation of PAs precontracted with U46619. TER had intermediary effect on K + response in PA and MA. TER exerted similar inhibition as LEF on PE-evoked contraction in MA, but had a milder effect in PA. In the latter, TER decreased E max by 42% and did not change EC 50 of PE. With calcium-free solution or nifedipine LEF still inhibited response to PE, suggesting the effect is not caused by Ca 2+ influx inhibition. Preliminary data showed that LEF inhibited contractile responses to K + and PE in human PAs, but surprisingly had no effect on U46619 response. Concentrations ≥100 μM inhibit proliferation of human pulmonary arterial smooth muscle cells(hPASMCs) LEF evoked a robust inhibitory effect of rat and human vascular tone at high, yet clinically relevant concentrations. Experiments are currently ongoing in order to clarify the actual mechanism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
More From: Revue des Maladies Respiratoires
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.